Gastro-oesophageal reflux disease: extinguishing that fire

  • G L Muntingh University of the Western Cape
Keywords: GORD, proton pump inhibitors, PPI, histamine 2-receptor antagonists, H2RAs, potassium-competitive acid blockers, oesophageal mucosal resistance, mucosal protective agents, reflux-inhibitors

Abstract

Gastro-oesophageal reflux disease (GORD) is a highly prevalent, chronic disorder. Information regarding this disease is limited and the management of these patients changes continuously. Proton-pump inhibitors (PPIs) remain the first-choice therapy in the treatment of GORD, but a consistent proportion of these patients continue to experience symptoms despite their use. Currently, other available agents include simple antacids and acid suppression therapy, including histamine 2-receptor antagonists (H2RAs), mucosal or cytoprotective agents and pro-motility agents. Recently, several new drugs have been used to increase the defensive properties of the gastric mucosa with promising results in randomised clinical trials. Deciding on appropriate therapy will depend on the diagnosis, side-effects and cost-effectiveness of the treatment.

Author Biography

G L Muntingh, University of the Western Cape

School of Pharmacy, University of the Western Cape, South Africa

Published
2021-10-25
Section
Review